诺和诺德全球首款口服GLP-1减重药疗效数据刷新纪录

美通社头条
Sep 24, 2025

、美通社消息:近日,《新英格兰医学杂志》(The New England Journal of Medicine)发表了来自3期试验OASIS 4的结果。此项试验评估了在研的每日一次口服司美格鲁肽片25 mg(Wegovy片剂)的有效性和安全性,标志着诺和诺德在推进肥胖症治疗方面达成一项重要的里程碑。在此项为期64周的试验中,口服司美格鲁肽片25mg联合生活方式干预,在307名肥胖或超重且伴有至少...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10